Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Gamida Cell

Main focus: Gene editing for the development of next-generation cell therapies

Company stage: Clinical

Diseases: Non-Hodgkin lymphoma (NHL), multiple myeloma, solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:GMDA)

Location: Boston, MA, USA



Partners: Editas Medicine

Gamida Cell is focusing on the development of next-generation cell therapies to treat cancer. The company has multiple pre-clinical programmes where CRISPR-Cas9 is being used to knock out important targets to improve potency, persistence and safety.


HashtagGamida Cell

Company: Gamida Cell
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine